Show simple item record

dc.contributor.authorHolmøy, Trygveen_US
dc.contributor.authorLøken-Amsrud, Kristin Ingeleiven_US
dc.contributor.authorBakke, Jacoben_US
dc.contributor.authorBeiske, Antonie Giæveren_US
dc.contributor.authorBjerve, Kristian Sen_US
dc.contributor.authorHovdal, Harald Olaven_US
dc.contributor.authorLilleås, Finnen_US
dc.contributor.authorMidgard, Runeen_US
dc.contributor.authorPedersen, Tomen_US
dc.contributor.authorSaltyte Benth, Jurateen_US
dc.contributor.authorTorkildsen, Øivinden_US
dc.contributor.authorWergeland, Stigen_US
dc.contributor.authorMyhr, Kjell-Mortenen_US
dc.contributor.authorMichelsen, Annikaen_US
dc.contributor.authorAukrust, Pålen_US
dc.contributor.authorUeland, Thoren_US
dc.date.accessioned2016-03-15T12:39:11Z
dc.date.available2016-03-15T12:39:11Z
dc.date.issued2013-09-19
dc.PublishedPLoS ONE 2013, 8(9)eng
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/1956/11654
dc.description.abstractBackground. Serum markers of inflammation are candidate biomarkers in multiple sclerosis (MS). ω-3 fatty acids are suggested to have anti-inflammatory properties that might be beneficial in MS. We aimed to explore the relationship between serum levels of inflammation markers and MRI activity in patients with relapsing remitting MS, as well as the effect of ω-3 fatty acids on these markers. Methods. We performed a prospective cohort study in 85 relapsing remitting MS patients who participated in a randomized clinical trial of ω-3 fatty acids versus placebo (the OFAMS study). During a period of 24 months 12 repeated magnetic resonance imaging (MRI) scans and nine serum samples were obtained. We measured 10 inflammation markers, including general down-stream markers of inflammation, specific markers of up-stream inflammatory pathways, endothelial action, and matrix regulation. Results. After Bonferroni correction, increasing serum levels of CXCL16 and osteoprotegerin were associated with low odds ratio for simultaneous MRI activity, whereas a positive association was observed for matrix metalloproteinase (MMP) 9. CXCL16 were also associated with low MRI activity the next month, but this was not significant after Bonferroni correction. In agreement with previously reported MRI and clinical results, ω-3 fatty acid treatment did not induce any change in the inflammation markers. Conclusions. Serum levels of CXCL16, MMP-9, and osteoprotegerin reflect disease activity in MS, but are not affected by ω-3 fatty acid treatment. CXCL16 could be a novel biomarker and potential predictor of disease activity in MS.en_US
dc.language.isoengeng
dc.publisherPLOS ONEeng
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.eng
dc.rights.urihttp://creativecommons.org/licenseseng
dc.titleInflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activityen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2015-11-20T11:02:34Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2013 Holmøy et al.
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0075021
dc.identifier.cristin1070201
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Neurology: 752
dc.subject.nsiVDP::Medisinske Fag: 700en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Except where otherwise noted, this item's license is described as This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.